Prevalence of FODMAP Intolerance and JHS in FGID and Association With Microbiome, Dyssynergic Defecation and Dietary Intervention
Prevalence of FODMAP Intolerance and JHS in FGID and Association With Microbiome, Dyssynergic Defecation and Dietary Intervention
Irritable bowel syndrome (IBS) is a disorder of gastrointestinal function characterized by
 abdominal symptoms and pain associated with alterations in bowel habit. The condition impacts
 on the quality of life of at least 10% of the population, impacts on activities of daily
 living and is associated with considerable direct and indirect costs to the individual, the
 health system and society. The etiology of IBS appears multifactorial and several mechanisms,
 among them mucosal inflammation, abnormal intestinal motility, visceral hypersensitivity and
 psychological factors, appear to be involved.

 An underlying pathophysiology, namely Joint Hypermobility (JH) and Joint Hypermobility
 Syndrome (JHS), that we are going to study, have recently gained increasing attention in
 patients with functional bowel disease.

 One factor which was shown in previous IBS-studies to reduce abdominal symptoms is a FODMAP
 diet.

 To identify FGID patients which profit most from different diagnostics and therapies (such as
 FODMAP diet) we are going to carry out a study analyzing different subtypes of FGID (in
 particular IBS, FD, functional abdominal pain/bloating) for demographics, clinical
 diagnostics (e.g. nutrient challenge testing, microbiome testing, anorectal manometry and MR
 defecography), comorbidities (in particular JH, JHS and psychological comorbidities) and
 treatment.
Functional gastrointestinal disorders (FGID) are common in the general population. Symptoms
 such as pain, nausea, bloating, diarrhea or constipation may occur. Irritable bowel syndrome
 (IBS) is the most common FGID with a prevalence in the range of 5-25%. Medical attention is
 sought by 20-75% of patients who meet diagnostic criteria for IBS at some time in their
 lives. Quality of life is often impaired in IBS patients. In previous studies a diet low in
 FODMAP was shown to reduce gastrointestinal symptoms in IBS patients.

 But still it is unknown which FGID patients (e.g. patients with irritable bowel syndrome,
 functional dyspepsia (FD), functional abdominal pain/bloating) profit most from such a diet
 which involves costs, time and significant lifestyle alteration.

 To test for food intolerances, standard hydrogen breath tests using fructose or lactose as
 challenge substance are still commonly used and do present a nutritional challenge, however
 the usefulness of information gained is questionable. Fructose intolerance is as prevalent in
 IBS as in healthy volunteers, in fact when tested with the usual doses of 25-50g, prevalence
 of fructose intolerance ranges between 53% and 73%. Testing (genetic) for hypolactasia, is
 often, even in the professional setting, misunderstood as lactose intolerance testing. Most
 patients, who do have hypolactasia, i.e. almost no activity of intestinal brush-border enzyme
 lactase, tolerate up to 12g of lactose per day, remain asymptomatic and therefore should not
 be considered lactose intolerant. In addition, one must realize, that the vast majority in
 the world is hypolactasic and hypolactasia, or rather lactase persistence, constitutes a norm
 variant.

 Recently it was shown that a standardized liquid mixed nutrient meal including 25g lactulose,
 but not with 15g lactulose, allows differentiation of IBS patients from healthy controls.
 This test, incorporating FODMAP lactulose, that, unlike lactose and fructose, is indigestible
 in all humans in the small intestine, plus a caloric load, reflecting a regular meal and
 everyday life, has therefore the potential to be a useful marker of nutrient intolerance in
 patients with suspected functional bowel disease.

 Additionally, associations between FGID and JH/JHS have been recognized in the past decade.
 JH/JHS constitutes a hereditary disorder of connective tissue in which patients often report
 non-musculoskeletal symptoms, among them gastrointestinal complaints. Previous studies in
 Europe and the U.S. have reported a JHS prevalence of 20% in the general population.

 A stringent approach to studying possibly JH and JHS-related changes with diagnostic and
 interventional arms, such as a nutrient challenge testing or dietary adaptation (i.e.FODMAP
 diet) has not yet been taken.

 Differences in the intestinal microbiome have been shown in IBS patients compared to healthy
 volunteers but not in JHS compared to non-JHS patients. Given the differences noted in
 patients' symptomatology, the preliminary data on gut function and the underlying structural
 abnormalities, the role of microbiome in relation to FGID and JHS is highly interesting and,
 as yet, unstudied. In recent years with the advent of more powerful sequencing tools, a
 number of studies have been published, that try to characterize the microbiome in IBS
 patients. Research on IBS-related changes of the microbiome is early and incomplete. The
 number of literature reviews regarding gut microbiome currently far exceeds the number of
 original articles reporting on the microbiome in functional bowel disease. IBS-specific
 interventional studies are even rarer and when performed, often lack control groups and the
 reality of multiple or repeated intervention, that characterize treatment of FGID. Therefore,
 and to identify patients according to their microbiome which profit most from therapeutic
 intervention (such as FODMAP diet) we are also going to analyze microbiome changes before and
 after FODMAP diet.

 Another pathological, impairing aspect of IBS patients is the intestinal hypersensitivity.
 Anorectal hypersensitivity measurement has been considered a hallmark for IBS for many years.
 We are routinely performing anorectal functions tests in our specialized unit. Recently we
 validated high-resolution anorectal manometry and rapid barostat bag measurements to assess
 visceral sensitivity; in a further study we assessed obstructive defecation when compared to
 magnetic resonance defecography. In an earlier study employing magnetic resonance
 defecography (MR defecography) we were able to show that MR defecography, apart from
 correlating well with the diagnosis of dyssynergic defecation suggested by anorectal
 manometry, additional pelvic floor abnormalities such as pelvic floor descent, cystocele and
 enterocele could be identified. Studying these measures in patients with suspected outlet
 obstruction in relation to JHS status, which is considered a risk factor for pelvic floor
 abnormalities, might lead to more focused diagnostic and therapeutic approaches in the future
 for patients who profit most from certain procedures.

 Considering all above mentioned facts we are going to carry out a study analyzing different
 subtypes of FGID (in particular IBS, FD, functional abdominal pain/bloating) for
 demographics, clinical diagnostics (e.g. nutrient challenge testing, microbiome testing,
 anorectal manometry and MR defecography), treatment (FODMAP diet) and comorbidities (in
 particular JH, JHS and psychological comorbidities) to identify FGID patients which profit
 most from different diagnostics and FODMAP diet.
Inclusion criteria for FGID patients:

 -  Functional bowel disease as per physician's diagnosis (medical judgement) and Rome IV
 criteria

 -  Signed Informed Consent after being informed

 -  Age 18-60 years

 Inclusion criteria for hepatology control cohort:

 -  Signed Informed Consent after being informed

 -  Age 18-60 years

 -  Patient in the ambulatory hepatology clinic

 Inclusion criteria for healthy volunteers:

 -  Signed informed consent after being informed

 -  Age 18-60 years

 Exclusion criteria for FGID patients:

 -  Inflammatory bowel disease

 -  Gastrointestinal malignancy

 -  Celiac Disease

 -  Known or suspected non-compliance, drug or alcohol abuse

 -  Previous large abdominal surgery likely to impact patient symptomatology

 -  Inability to follow the procedures of the study, e.g. due to language problems,
 dementia, etc. of the participant

 -  Previous enrollment into the current study

 -  Use of antibiotics in the previous 4 weeks before enrolment

 Exclusion criteria for hepatology control cohort:

 -  Previous diagnosed functional gastrointestinal disorders

 Exclusion criteria for healthy volunteers:

 -  Previous diagnosed functional gastrointestinal disorders